Astrocytoma medical therapy
|
Astrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Study |
|
Astrocytoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Astrocytoma medical therapy |
|
Risk calculators and risk factors for Astrocytoma medical therapy |
Overview
Medical Therapy
- Treatment depends on the size and type of tumor and the child's general health. The goals of treatment may be to cure the tumor, relieve symptoms, and improve brain function or the child's comfort
- Two related drugs have been shown to shrink or stabilize supependymal giant cell tumors: rapamycin and everolimus. These both belong to the mTOR inhibitor class of immunosuppressants, and are both contraindicated in patients with severe infections.
- Rapamycin showed efficacy in five cases of SEGA in TSC patients, shrinking their tumor volumes by an average of 65%. However, after the drug was stopped, the tumors regrew.
- Everolimus which has a similar structure as rapamycin, but with slightly increased bioavailability and shorter half-life, was studied in 28 patients with SEGA. There was a significant reduction in SEGA size in 75% of the patients, and a mild improvement in their seizures. Everolimus was approved for the treatment of SEGA by the US Food and Drug Administration (FDA) in October, 2010.
- The following are treatments for specific types of tumors:
- Medicines used to treat primary brain tumors in children include:
- Corticosteroids to reduce brain swelling
- Diuretics (water pills) to reduce brain swelling and pressure
- Anticonvulsants to reduce or prevent seizures
- Pain medicines
- Comfort measures, safety measures, physical therapy, occupational therapy, and other such steps may be required to improve quality of life.
- Despite decades of therapeutic research, curative intervention is still nonexistent for high grade astrocytomas; patient care ultimately focuses on palliative management.